Friedo Wilhelm Dekker

Friedo Wilhelm Dekker

Auto-generated profile, based on publicly available information

Friedo Wilhelm Dekker

Department of Clinical Epidemiology, Leiden University Medical Center , Leiden

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Kidney International
Verified
Journal Article
Open access
PDF file
GMGeir Mjøen
Geir Mjøen
SHStein Hallan
Stein Hallan
AHAnders Hartmann
Anders Hartmann
AFAksel Foss
Aksel Foss
KMKarsten Midtvedt
Karsten Midtvedt
HHHallvard Holdaas
Hallvard Holdaas
Previous studies have suggested that living kidney donors maintain long-term renal function and experience no increase in cardiovascular or all-cause mortality. However, most analyses have included control groups less healthy than the living donor population and have had relatively short follow-up periods. Here we compared long-term renal function and cardiovascular and all-cause mortality in living kidney donors compared with a control group of individuals who would have been eligible for donation. All-cause mortality, cardiovascular mortality, and end-stage renal disease (ESRD) was identified in 1901 individuals who donated a kidney during 1963 through 2007 with a median follow-up of 15.1 years. A control group of 32,621 potentially eligible kidney donors was selected, with a median follow-up of 24.9 years. Hazard ratio for all-cause death was significantly increased to 1.30 (95% confidence interval 1.11–1.52) for donors compared with controls. There was a significant corresponding increase in cardiovascular death to 1.40 (1.03–1.91), while the risk of ESRD was greatly and significantly increased to 11.38 (4.37–29.6). The overall incidence of ESRD among donors was 302 cases per million and might have been influenced by hereditary factors. Immunological renal disease was the cause of ESRD in the donors. Thus, kidney donors are at increased long-term risk for ESRD, cardiovascular, and all-cause mortality compared with a control group of non-donors who would have been eligible for donation.

28 October 2009 in JAMA
Verified
Journal Article
Open access
PDF file
DJDinanda J De Jager
Dinanda J De Jager
DGDiana C Grootendorst
Diana C Grootendorst
KJKitty J Jager
Kitty J Jager
PDPaul C Van Dijk
Paul C Van Dijk
LTLonneke M J Tomas
Lonneke M J Tomas
FDFriedo W Dekker
Friedo W Dekker
Patients with chronic kidney disease are at higher mortality risk compared with the general population.1,2 Cardiovascular disease is the most common cause of death in these patients, as noted more than 30 years ago.3 Several studies have shown that cardiovascular disease accounts for 40% to 50% of deaths in patients with end-stage renal disease.4-6 Cardiovascular mortality risk in patients receiving hemodialysis or peritoneal dialysis is observed to be 10 to 20 times that in the general population.4,6

24 August 2013 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MNMarlies Noordzij
Marlies Noordzij
KLKaren Leffondré
Karen Leffondré
KSKarlijn J. van Stralen
Karlijn J. van Stralen
carmine zoccalicarmine zoccali
carmine zoccali
FDFriedo W. Dekker
Friedo W. Dekker
KJKitty J. Jager
Kitty J. Jager
Survival analyses are commonly applied to study death or other events of interest. In such analyses, so-called competing risks may form an important problem. A competing risk is an event that either hinders the observation of the event of interest or modifies the chance that this event occurs. For example, when studying death on dialysis, receiving a kidney transplant is an event that competes with the event of interest. Conventional methods for survival analysis ignoring the competing event(s), such as the Kaplan–Meier method and standard Cox proportional hazards regression, may be inappropriate in the presence of competing risks, and alternative methods specifically designed for analysing competing risks data should then be applied. This problem deserves more attention in nephrology research and in the current article, we therefore explain the problem of competing risks in survival analysis and how using different techniques may affect study results.

1 June 2010 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
WMWieneke Marleen Michels
Wieneke Marleen Michels
DGDiana Carina Grootendorst
Diana Carina Grootendorst
MVMarion Verduijn
Marion Verduijn
EEElise Grace Elliott
Elise Grace Elliott
FDFriedo Wilhelm Dekker
Friedo Wilhelm Dekker
RKRaymond Theodorus Krediet
Raymond Theodorus Krediet
Background and objectives: We compared the estimations of Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations to a gold standard GFR measurement using 125I-iothalamate, within strata of GFR, gender, age, body weight, and body mass index (BMI). Design, setting, participants, & measurements: For people who previously underwent a GFR measurement, bias, precision, and accuracies between measured and estimated kidney functions were calculated within strata of the variables. The relation between the absolute bias and the variables was tested with linear regression analysis. Results: Overall (n = 271, 44% male, mean measured GFR 72.6 ml/min per 1.73 m2 [SD 30.4 ml/min per 1.73 m2]), mean bias was smallest for MDRD (P < 0.01). CKD-EPI had highest accuracy (P < 0.01 compared with Cockcroft-Gault), which did not differ from MDRD (P = 0.14). The absolute bias of all formulas was related to age. For MDRD and CKD-EPI, absolute bias was also related to the GFR; for Cockcroft-Gault, it was related to body weight and BMI as well. In all extreme subgroups, MDRD and CKD-EPI provided highest accuracies. Conclusions: The absolute bias of all formulas is influenced by age; CKD-EPI and MDRD are also influenced by GFR. Cockcroft-Gault is additionally influenced by body weight and BMI. In general, CKD-EPI gives the best estimation of GFR, although its accuracy is close to that of the MDRD.

1 November 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AGAbraham Goorhuis
Abraham Goorhuis
DBDennis Bakker
Dennis Bakker
JCJeroen Corver
Jeroen Corver
SDSylvia B. Debast
Sylvia B. Debast
CHCeline Harmanus
Celine Harmanus
EKEd J. Kuijper
Ed J. Kuijper
Background. Since 2005, an increase in the prevalence of Clostridium difficile infection (CDI) due to polymerase chain reaction ribotype 078 has been

1 June 2003 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
CTC.B. Terwee
C.B. Terwee
FDF.W. Dekker
F.W. Dekker
WWW.M. Wiersinga
W.M. Wiersinga
MPM.F. Prummel
M.F. Prummel
PBP.M.M. Bossuyt
P.M.M. Bossuyt